Join to access to all OVN content. Join for Free
10 Tips for a Successful MSL Interview with Sue Watson
Sue Watson Oncology Medical Affairs MSL Interview Tips Janssen Pharmaceuticals Successful MSL Interview

10 Tips for a Successful MSL Interview with Sue Watson


Share This Article


Summary

My guest today is Sue Watson. Sue is the Scientific Director, Oncology Medical Affairs, Janssen Pharmaceuticals, Johnson & Johnson. Our topic today is 10 Tips for a Successful MSL interview.

In this episode:

  • Who is Sue and what she’s doing
  • Sue’s advice as candidates start to prepare the interview
  • Tips for a successful MSL Interview
  • Bring interest and enthusiasm
  • Know the company
  • Know who is interviewing you
  • Know the role of an MSL
  • Prepare for your presentation
  • Anticipate the questions they will ask you
  • Prepare a 30-60-90 day plan
  • Prepare a list of questions for you to ask the interviewers
  • Dress for the interview
  • Send thank you email
  • Advice to aspiring MSLs trying to break into the role

Click for Source
Sue Watson, Oncology Medical Affairs, MSL Interview Tips, Janssen Pharmaceuticals, Successful MSL Interview

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation
Partner Avatar Bridget Rasmusson

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Article
Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2
OVN Avatar Guillaume Beinse, MD, Virgile Tellier, Valentin Charvet, MSc, Eric Deutsch, MD, PhD, Isabelle Borget, PharmD, PhD, Christophe Massard, MD, PhD., Antoine Hollebecque, MD, PhD, and Loic Verlingue, MD

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2

Article
Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
OVN Avatar Jaques van Heerden, MD, Mohamed Zaghloul, MD, Anouk Neven, MSc, Teresa de Rojas, MD, PhD, Jennifer Geel, MD, Catherine Patte, MD, Joyce Balagadde-Kambugu, MD, Peter Hesseling, MD, Francine Tchintseme, MD, Eric Bouffet, MD, and Laila Hessissen, MD

Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Explore OVN